Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Salarius Pharmaceuticals Inc SLRX

Healthcare Biotechnology
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and... see more

Recent & Breaking News (NDAQ:SLRX)

Clinical Data on Salarius Pharmaceuticals' Seclidemstat in Patients with MDS and CMML Presented at the 2024 European Hematology Association Annual Meeting

GlobeNewswire June 17, 2024

Salarius Pharmaceuticals Announces 1-for-8 Reverse Stock Split

GlobeNewswire June 12, 2024

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 22, 2024

Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses

GlobeNewswire February 22, 2024

Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders

GlobeNewswire January 16, 2024

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals' Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

GlobeNewswire January 3, 2024

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

GlobeNewswire November 7, 2023

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

GlobeNewswire August 10, 2023

Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources

GlobeNewswire August 8, 2023

Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients

GlobeNewswire July 11, 2023

Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress

GlobeNewswire June 12, 2023

Salarius Pharmaceuticals Announces Closing of $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire May 16, 2023

Salarius Pharmaceuticals Announces $6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

GlobeNewswire May 12, 2023

Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update

GlobeNewswire May 11, 2023

FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals' Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma

GlobeNewswire May 9, 2023

Salarius Pharmaceuticals Reports No Adverse Safety Signals from Two Good Laboratory Practice Toxicology Studies with its Targeted Protein Degrader SP-3164

GlobeNewswire May 1, 2023

Salarius Pharmaceuticals Presents Compelling Data in Two SP-3164 Targeted Protein Degrader Posters at the American Association for Cancer Research Annual Meeting

GlobeNewswire April 20, 2023

Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

GlobeNewswire April 4, 2023

Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

GlobeNewswire March 27, 2023

Salarius Pharmaceuticals Announces Two Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting

GlobeNewswire March 15, 2023